3. Neoprobe ( NEOP) is a biomedical company that develops and commercializes oncology products. The company markets a range of medical devices, its neoprobe gamma detection systems (GDS). In addition to ITS medical device products, it has two radiopharmaceutical products, Lymphoseek and RIGScan CR, in advanced phases of clinical development. The company is expected to report its first quarter 2011 results on Apr. 28. Total revenue is forecast to increase 10.4% to $2.9 million from $2.7 million in the year-ago quarter. Net loss is seen narrowing to $1.7 million or 2 cents per share, as compared to $2.5 million or 3 cents per share reported in the first quarter of 2010. Recently, LifeSci Advisors LLC, a leading provider of investment research and investor relations services in the life sciences sector, initiated coverage on the stock. "Lymphoseek, Neoprobe's new small molecule radiopharmaceutical agent designed to detect lymph nodes during intraoperative lymphatic mapping procedures for patients with various forms of cancer, has the potential to become a 'best in class' imaging diagnostic," said Andrew I. McDonald, Ph.D., Managing Director at LifeSci Advisors. Of the four analysts covering the stock, 75% recommend it a buy, while the remaining rate a hold. There are no sell ratings on the stock. On average, analysts expect an upside of 21.9% to $5.81 in value from current levels. The stock has gained 146% in the past one year.